SynthesisApplied biochemistry and biotechnology2026
Microbiome-Driven Therapeutic Strategies for Type 2 Diabetes: A Systematic Review of Microbiota Modulation, Glycaemic Outcomes, and Transplantation.
Synthesis in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (T2DM) arises from the body's ineffective use or production of insulin. Recent research highlights the significant role of the gut microbiome in metabolism and immunity, indicating that microbial dysbiosis may be associated with T2DM development. This systematic review will explore the link between gut dysbiosis and Type 2 Diabetes Mellitus (T2DM), assess the impact of microbially-targeted therapies such as probiotics, prebiotics, dietary changes, and fecal microbiota transplantation (FMT) on glycaemic and metabolic outcomes in adults with T2DM, and determine if clinical trials validate the application of these therapies for T2DM treatment. An extensive literature search was conducted using PubMed up to January 2024, adhering to PRISMA 2020 guidelines, to identify eligible studies. The studies included were randomized controlled trials or observational studies reporting measurable outcomes related to metabolic health in adults aged 18 and older. A total of 25 studies show that individuals with Type 2 Diabetes Mellitus (T2DM) have lower gut microbial diversity, featuring fewer butyrate-producing bacteria and more inflammation-related bacteria. Probiotic supplementation and dietary fiber intake significantly improve hemoglobin A1c (HbA1c) levels and insulin sensitivity in T2DM patients. Gut microbiota dysbiosis is linked to Type 2 Diabetes Mellitus (T2DM), suggesting that the gut microbiome could be a therapeutic focus. However, while interventions like dietary changes, probiotics, and fecal microbiota transplantation show potential, current evidence does not support their routine clinical application. Recommendations for microbiome interventions should rely on strong evidence from effective longitudinal clinical trials verifying both efficacy and safety.
Indexed as
Identifiers
42573711What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.